Enfusion, Inc.
ENFN · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $202 | $175 | $150 | $112 |
| % Growth | 15.5% | 16.1% | 34.6% | – |
| Cost of Goods Sold | $65 | $58 | $47 | $32 |
| Gross Profit | $137 | $117 | $103 | $80 |
| % Margin | 67.8% | 67% | 68.7% | 71.5% |
| R&D Expenses | $27 | $20 | $17 | $153 |
| G&A Expenses | $79 | $65 | $69 | $151 |
| SG&A Expenses | $104 | $85 | $98 | $202 |
| Sales & Mktg Exp. | $25 | $20 | $29 | $52 |
| Other Operating Expenses | $0 | $0 | -$1 | -$1 |
| Operating Expenses | $131 | $105 | $115 | $356 |
| Operating Income | $6 | $12 | -$12 | -$276 |
| % Margin | 3.1% | 6.8% | -8% | -247% |
| Other Income/Exp. Net | $1 | -$0 | -$0 | -$6 |
| Pre-Tax Income | $7 | $11 | -$12 | -$282 |
| Tax Expense | $5 | $2 | $1 | $1 |
| Net Income | $3 | $6 | -$13 | -$282 |
| % Margin | 1.4% | 3.5% | -8.8% | -252.7% |
| EPS | 0.019 | 0.1 | -0.16 | -4.3 |
| % Growth | -81.2% | 162.5% | 96.3% | – |
| EPS Diluted | 0.013 | 0.072 | -0.1 | -4.3 |
| Weighted Avg Shares Out | 92 | 88 | 85 | 66 |
| Weighted Avg Shares Out Dil | 130 | 129 | 133 | 66 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $5 |
| Depreciation & Amortization | $0 | $10 | $7 | $4 |
| EBITDA | $6 | $22 | -$5 | -$272 |
| % Margin | 3.1% | 12.6% | -3.6% | -243.4% |